Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record.

5‐HT4receptor agonists: similar but not the same

Open access
De Maeyer, J. H., Lefebvre, R. A., Schuurkes, J. A. J. · 2008 · Neurogastroenterology & Motility

Abstract

Abstract 5‐Hydroxytryptamine 4(5‐HT 4) receptors are an interesting target for the management of patients in need of gastrointestinal (GI) promotility treatment. They have proven therapeutic potential to treat patients with GI motility disorders. Lack of selectivity for the 5‐HT 4 receptor has limited the clinical success of the agonists used until now. For instance, next to their affinity for 5‐HT 4 receptors, both cisapride and tegaserod have appreciable affinity for other receptors, channels or transporters [e.g. cisapride: human ether‐a‐go‐go‐related gene (hERG) is K+channel and tegaserod: 5‐HT 1 and 5‐HT 2 receptors]. Adverse cardiovascular events observed with these compounds are not 5‐HT 4 receptor‐related. Recent efforts have led to the discovery of a series of selective 5‐HT 4 receptor ligands, with prucalopride being the most advanced in clinical development. The selectivity of these new compounds clearly differentiates them from the older generation compounds by minimizing the potential of target‐unrelated side effects. The availability of selective agonists enables the focus to shift to the exploration of 5‐HT 4 receptor‐related differences between agonists. Based on drug‐ and tissue‐related properties (e.g. differences in receptor binding, receptor density, effectors, coupling efficiency), 5‐HT 4 receptor agonists are able to express tissue selectivity, i.e. behave as a partial agonist in some and as a full agonist in other tissues. Furthermore, the concept of ligand‐directed signalling offers great opportunities for future drug development by enlarging the scientific basis for the generation of agonist‐specific effects in different cell types, tissues or organs. Selective 5‐HT 4 receptor agonists might thus prove to be innovative drugs with an attractive safety profile for better treatment of patients suffering from hypomotility disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2982.2007.01059.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 248

Metadata

Authors
De Maeyer, J. H., Lefebvre, R. A., & Schuurkes, J. A. J.
Venue
Neurogastroenterology & Motility
Publisher
Wiley
Published
2008-01-10
Volume
20
Issue
2
Pages
99-112
ISSN
  • 1350-1925 (ISSN-L)
  • 1365-2982
OpenAlex
W1501397556
Cited by
248
References
0
FWCI
9.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5‐HT4receptor agonists: similar but not the same. https://app.cochat.ai/papers/10.1111/j.1365-2982.2007.01059.x
The paper
De Maeyer, J. H., Lefebvre, R. A., & Schuurkes, J. A. J. (2008). 5‐HT4receptor agonists: similar but not the same. Neurogastroenterology & Motility. https://doi.org/10.1111/j.1365-2982.2007.01059.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.